Literature DB >> 33398561

Percutaneous transhepatic cholangioscopy using a single-operator cholangioscope (pSOC), a retrospective, observational, multicenter study.

Christian Gerges1, Alain García Vázquez2,3, Andrea Tringali4,5, Juan Manuel Verde6,7, Tobias Dertmann1, Eduardo Houghton8, Alessandro Cina5, Torsten Beyna1, Federico Sylvestre Begnis8, Margherita Pizzicannella2,3, Mariano Palermo8, Silvana Perretta2,3, Guido Costamagna4,5, Jacques Marescaux3, Horst Neuhaus1, Ivo Boškoski4,5, Mariano Eduardo Giménez2,3,8.   

Abstract

BACKGROUND AND AIMS: Percutaneous cholangioscopy (PC) is more complex and invasive than a transpapillary approach, with the need for a large percutaneous tract of 16 French (Fr) on average in order to advance standard percutaneous cholangioscopes. The aim of this study was to investigate whether percutaneous single-operator cholangioscopy (pSOC) using the SpyGlass™ DS system is feasible, safe, and effective in PC for diagnostic and therapeutic indications.
MATERIALS AND METHODS: The data of 28 patients who underwent pSOC in 4 tertiary referral centers were retrospectively analyzed. Technical and clinical success for therapeutic procedures was assessed as well as diagnostic accuracy of pSOC-guided biopsies and visualization. Adverse events and the required number and size of dilatations were reviewed.
RESULTS: 25/28 (89%) patients had a post-surgical altered anatomy. The average number of percutaneous dilatations prior to pSOC was 1.25 with a mean dilatation size of 11 French. Histopathology showed a 100% accuracy. Visual impression showed an overall accuracy of 96.4%. Technical and clinical success was achieved in 27/28 (96%) of cases. Adverse events occurred in 3/28 (10.7%) cases.
CONCLUSION: pSOC is a feasible, safe, and effective technique for diagnostic and therapeutic indications. It may be considered an alternative approach in clinical cases where gastrointestinal anatomy is altered. It has the potential to reduce peri-procedural adverse events and costs. Prospective randomized-controlled trials are necessary to confirm the previously collected data.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Altered biliary anatomy; Percutaneous SpyGlassDS; Percutaneous cholangioscopy; SpyGlass

Mesh:

Year:  2021        PMID: 33398561     DOI: 10.1007/s00464-020-08176-1

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  33 in total

1.  Removal of bile duct foreign body by using spyglass and spybite.

Authors:  Kanat Ransibrahmanakul; Chhaya Hasyagar; Thomas Prindiville
Journal:  Clin Gastroenterol Hepatol       Date:  2009-09-10       Impact factor: 11.382

2.  Reliability and accuracy of a novel classification system using peroral cholangioscopy for the diagnosis of bile duct lesions.

Authors:  Carlos Robles-Medranda; Manuel Valero; Miguel Soria-Alcivar; Miguel Puga-Tejada; Roberto Oleas; Jesenia Ospina-Arboleda; Haydee Alvarado-Escobar; Jorge Baquerizo-Burgos; Carlos Robles-Jara; Hannah Pitanga-Lukashok
Journal:  Endoscopy       Date:  2018-06-28       Impact factor: 10.093

3.  Percutaneous transhepatic cholangioscopic treatment for hepatolithiasis: an evaluation of long-term results and risk factors for recurrence.

Authors:  S K Lee; D W Seo; S J Myung; E T Park; B C Lim; H J Kim; K S Yoo; H J Park; Y H Joo; M H Kim; Y I Min
Journal:  Gastrointest Endosc       Date:  2001-03       Impact factor: 9.427

4.  Digital single-operator peroral cholangioscopy-guided biopsy sampling versus ERCP-guided brushing for indeterminate biliary strictures: a prospective, randomized, multicenter trial (with video).

Authors:  Christian Gerges; Torsten Beyna; Raymond S Y Tang; Farzan Bahin; James Y W Lau; Erwin van Geenen; Horst Neuhaus; Duvvur Nageshwar Reddy; Mohan Ramchandani
Journal:  Gastrointest Endosc       Date:  2019-11-25       Impact factor: 9.427

5.  Per-oral video cholangiopancreatoscopy with narrow-band imaging for the evaluation of indeterminate pancreaticobiliary disease.

Authors:  Rawad Mounzer; Gregory L Austin; Sachin Wani; Brian C Brauer; Norio Fukami; Raj J Shah
Journal:  Gastrointest Endosc       Date:  2016-11-25       Impact factor: 9.427

Review 6.  Intraductal biliopancreatic imaging: European Society of Gastrointestinal Endoscopy (ESGE) technology review.

Authors:  Andrea Tringali; Arnaud Lemmers; Volker Meves; Grischa Terheggen; Jürgen Pohl; Guido Manfredi; Michael Häfner; Guido Costamagna; Jacques Devière; Horst Neuhaus; Fabrice Caillol; Marc Giovannini; Cesare Hassan; Jean-Marc Dumonceau
Journal:  Endoscopy       Date:  2015-07-06       Impact factor: 10.093

Review 7.  Percutaneous Transhepatic Cholangioscopy.

Authors:  Sameer Ahmed; Todd R Schlachter; Kelvin Hong
Journal:  Tech Vasc Interv Radiol       Date:  2015-07-15

8.  Percutaneous trans-hepatic cholangioscopy and lithotripsy in the treatment of intrahepatic stones: a study with 5 year follow-up.

Authors:  Y H Yeh; M H Huang; J C Yang; L R Mo; J Lin; S K Yueh
Journal:  Gastrointest Endosc       Date:  1995-07       Impact factor: 9.427

Review 9.  Cholangioscopy.

Authors:  Michael Darcy; Daniel Picus
Journal:  Tech Vasc Interv Radiol       Date:  2008-06

10.  Analysis of percutaneous transhepatic cholangioscopy-related complications and the risk factors for those complications.

Authors:  H-C Oh; S K Lee; T Y Lee; S Kwon; S S Lee; D-W Seo; M-H Kim
Journal:  Endoscopy       Date:  2007-08       Impact factor: 10.093

View more
  2 in total

1.  Percutaneous Transhepatic Electrohydraulic Lithotripsy for the Treatment of Difficult Bile Stones.

Authors:  Anna Maria Ierardi; Giovanni Maria Rodà; Letizia Di Meglio; Giuseppe Pellegrino; Paolo Cantù; Daniele Dondossola; Giorgio Rossi; Gianpaolo Carrafiello
Journal:  J Clin Med       Date:  2021-03-29       Impact factor: 4.241

Review 2.  Difficult Biliary Stones: A Comprehensive Review of New and Old Lithotripsy Techniques.

Authors:  Edoardo Troncone; Michelangela Mossa; Pasquale De Vico; Giovanni Monteleone; Giovanna Del Vecchio Blanco
Journal:  Medicina (Kaunas)       Date:  2022-01-13       Impact factor: 2.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.